FDA Grants Priority Review for Daiichi Sankyo ’s New Drug Application for FLT3 Inhibitor Quizartinib for Treatment of Patients with Relapsed/Refractory FLT3-ITD AML

Tokyo, Munich and Basking Ridge, NJ– (November 21, 2018)– Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced that the U.S. Food and Drug Administration (FDA) has accepted a New Drug Application (NDA) and granted...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news